Antonius van Dijk - 21 Jan 2022 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Role
Chief Technology Officer
Signature
By: /s/ Christine Klaskin, attorney-in-fact
Issuer symbol
INKT
Transactions as of
21 Jan 2022
Transactions value $
$0
Form type
4
Filing time
25 Jan 2022, 16:19:36 UTC
Previous filing
20 Oct 2021
Next filing
12 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INKT Stock Option (Right to Buy) Award $0 +62,500 $0 62,500 21 Jan 2022 Common Stock 62,500 $3.12 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an option to purchase shares of the common stock, which vests as to 35% of the underlying shares on January 21, 2025 and as to the remaining 65% of the underlying shares on January 21, 2026; provided that the Reporting Person maintains a business relationship with the Issuer through each such vesting date.